Artigos com autorizações de acesso público - Amalio TelentiSaiba mais
Não disponíveis em nenhum local: 17
Rever
Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites
T Long, M Hicks, HC Yu, WH Biggs, EF Kirkness, C Menni, J Zierer, ...
Nature genetics 49 (4), 568-578, 2017
Autorizações: UK Medical Research Council, National Institute for Health Research, UK …
Rever
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
R Lubomirov, J di Iulio, A Fayet, S Colombo, R Martinez, C Marzolini, ...
Pharmacogenetics and genomics 20 (4), 217-230, 2010
Autorizações: Swiss National Science Foundation
Rever
Pharmacogenetics of anti-HIV drugs
A Telenti, UM Zanger
Annu. Rev. Pharmacol. Toxicol. 48 (1), 227-256, 2008
Autorizações: Swiss National Science Foundation
Rever
Safety concerns about CCR5 as an antiviral target
A Telenti
Current Opinion in HIV and AIDS 4 (2), 131-135, 2009
Autorizações: Swiss National Science Foundation
Rever
A validated assay by liquid chromatography–tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients
M Aouri, A Calmy, B Hirschel, A Telenti, T Buclin, M Cavassini, A Rauch, ...
Journal of Mass Spectrometry 48 (5), 616-625, 2013
Autorizações: Swiss National Science Foundation
Rever
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction
A Fayet, A Béguin, BM de Tejada, S Colombo, M Cavassini, S Gerber, ...
Therapeutic drug monitoring 30 (4), 511-522, 2008
Autorizações: Swiss National Science Foundation
Rever
Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7
M Rotger, M Saumoy, K Zhang, M Flepp, R Sahli, L Decosterd, A Telenti, ...
Pharmacogenetics and genomics 17 (10), 885-890, 2007
Autorizações: Swiss National Science Foundation
Rever
The role of tripartite motif family members in mediating susceptibility to HIV-1 infection
N Rahm, A Telenti
Current Opinion in HIV and AIDS 7 (2), 180-186, 2012
Autorizações: Swiss National Science Foundation
Rever
Genomics of host–pathogen interactions
A Rausell, A Telenti
Current opinion in immunology 30, 32-38, 2014
Autorizações: Swiss National Science Foundation
Rever
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics
M Arab-Alameddine, LA Décosterd, T Buclin, A Telenti, C Csajka
Expert opinion on drug metabolism & toxicology 7 (5), 609-622, 2011
Autorizações: Swiss National Science Foundation
Rever
Evolutionary genomics and HIV restriction factors
N Pyndiah, A Telenti, A Rausell
Current opinion in HIV and AIDS 10 (2), 79-83, 2015
Autorizações: Swiss National Science Foundation
Rever
Host factors associated with outcome from primary human immunodeficiency virus-1 infection
A Telenti, M Carrington
Current Opinion in HIV and AIDS 3 (1), 28-35, 2008
Autorizações: Swiss National Science Foundation
Rever
Rethinking the medical record
A Telenti, SR Steinhubl, EJ Topol
The Lancet 391 (10125), 1013, 2018
Autorizações: US National Institutes of Health
Rever
Machine learning to decode genomics
A Telenti
Clinical Chemistry 66 (1), 45-47, 2020
Autorizações: US National Institutes of Health
Rever
Host Response in HIV Infection
PJ McLaren, A Telenti
Molecular Microbiology: Diagnostic Principles and Practice, 655-662, 2016
Autorizações: Swiss National Science Foundation
Rever
Humans Resembling Natural Hosts of SIV
A Telenti
Natural Hosts of SIV, 353-366, 2014
Autorizações: Swiss National Science Foundation
Rever
Genetic Associations with Resistance to HIV-1 Infection, Viral Control and Protection Against Disease
J Fellay, A Telenti
Models of Protection Against HIV/SIV, 319-334, 2012
Autorizações: Swiss National Science Foundation
Disponíveis em algum local: 199
Rever
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
D Pinto, YJ Park, M Beltramello, AC Walls, MA Tortorici, S Bianchi, ...
Nature 583 (7815), 290-295, 2020
Autorizações: US Department of Energy, US National Institutes of Health
Rever
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ...
Gastroenterology 138 (4), 1338-1345. e7, 2010
Autorizações: Swiss National Science Foundation
Rever
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, ...
Nature 602 (7898), 664-670, 2022
Autorizações: Bill & Melinda Gates Foundation, US National Institutes of Health, Howard …
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.